Key result
Acarbose 200-mg attenuated the acute changes in blood glucose and flow-mediated dilation following saccharose ingestion compared to placebo.
Why the study?
Does acute administration of acarbose prevent acute endothelial dysfunction in subjects with impaired glucose tolerance?
RCT (n=28)
double-blind
randomized
Does acute administration of acarbose prevent acute endothelial dysfunction in subjects with impaired glucose tolerance?
Acute reduction of postchallenge hyperglycemia with acarbose prevents acute endothelial dysfunction in subjects with impaired glucose tolerance.
Answers are grounded in this paper and cite their sources.
Acarbose may preserve endothelial function in IGT; confirms postprandial hyperglycemia as a modifiable acute vascular target.
OBJECTIVES: To investigate whether selective reduction of postchallenge hyperglycaemia influences acute endothelial dysfunction, a very early manifestation of vascular disease, in patients with impaired glucose tolerance. METHODS: In a randomized, double-blind, placebo-controlled, cross-over study the acute effect of 200-mg acarbose was investigated in 28 subjects with diagnosed impaired glucose tolerance. Flow-mediated dilation (FMD) of the brachial artery was determined as a measure of endothelial function before and 2 and 3 h after ingestion of 100-g saccharose. Asymmetrical dimethylarginine (ADMA) was measured by high-performance liquid chromatography. RESULTS: A negative correlation was observed between the changes of glucose and FMD (r = 0.416, P = 0.0018) 2 h after ingestion of saccharose. At 3 h, neither blood glucose nor FMD were different from baseline. Changes of both blood glucose (P = 0.0007) and FMD (P = 0.046) were significantly lower after administration of acarbose. Subgroup analysis revealed that the effect of acarbose was restricted to those subjects with an increase of blood glucose above the median increase of glycaemia. No changes of plasma ADMA were observed. CONCLUSIONS: Our data clearly demonstrate that the postchallenge alteration of vascular function in patients with impaired glucose tolerance is caused by the acute elevation of glycaemia but not mediated by ADMA.
No takes yet. Share an insight, caveat, or question.
Wascher et al. (2005) conducted an RCT in impaired glucose tolerance (n=28). acarbose vs. placebo was evaluated on Changes of blood glucose and flow-mediated dilation (FMD) (p=P=0.0007 for blood glucose, P=0.046 for FMD). Acarbose 200-mg attenuated the acute changes in blood glucose and flow-mediated dilation following saccharose ingestion compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: